Clinically Significant Drug Interactions among Nursing Home Residents with ADRD
患有 ADRD 的疗养院居民中具有临床意义的药物相互作用
基本信息
- 批准号:10704029
- 负责人:
- 金额:$ 70.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-15 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse drug eventAdverse eventAffectAlzheimer&aposs disease related dementiaCessation of lifeClinical assessmentsComputer softwareDangerousnessDataData SetDatabasesDoseDrug InteractionsDrug PrescriptionsDrug usageElderlyElectronic Health RecordFatigueFractureFutureGoalsHealth InsuranceHealth PersonnelHemorrhageHospitalizationImpaired cognitionIndividualInjuryJoint DislocationLinkMedicalMedicareMedicare claimMedication ManagementMethodologyMethodsMorbidity - disease rateNational Institute on AgingNatureNursing HomesOutcomePainPharmaceutical PreparationsPolypharmacyPopulationProviderRecordsRegimenResearchResearch PersonnelRiskRisk FactorsScreening ResultSeriesSubgroupSymptomsTestingTimeValidationadverse outcomeanalytical methodclinical practiceclinically actionableclinically significantdata resourcedisabilityepidemiology studyfall injuryfall riskfallsfrailtyfunctional declinehigh riskimprovedinnovationmodifiable riskmultidisciplinarymultiple chronic conditionsnovelnovel therapeuticsrandomized, clinical trialsrisk minimizationscreeningvalidation studies
项目摘要
PROJECT SUMMARY
Polypharmacy is common among nursing home (NH) residents and is most prevalent among residents with
Alzheimer's Disease and Related Dementias (ADRD) due to their high burden of multiple chronic conditions that
predispose them to medication use. Polypharmacy is dangerous for NH residents with ADRD because it
substantially increases the risk of drug interactions. Fall-related injuries, including fractures, joint dislocations,
and hemorrhages, are one of the most common and impactful adverse outcomes of drug interactions and result
in morbidity, disability, and death. Many theoretical interactions between drugs have been identified and
healthcare providers believe that drug interactions are common and harmful among older NH residents with
ADRD, yet limited data exist about which interactions are most clinically significant. Given that drug interactions
resulting from polypharmacy are likely a major, yet modifiable, cause of fall-related injuries among older NH
residents with ADRD, identifying drug interactions and their effects is essential for avoiding fall-related injuries.
Thus, the overall objective of this proposal is to identify, test, and validate clinically significant drug interactions
in NH residents with ADRD through a series of rigorous epidemiological studies that employ novel drug
interaction screening and causal inference methods. The central hypothesis is that multiple clinically significant
drug interactions will increase the risk of fall-related injuries, and that this risk will be greatest among individuals
with the most severe cognitive impairment and on higher medication doses. This hypothesis will be tested
through three specific aims: Aim 1 (Screening), Conduct hypothesis-free high-throughput semi-automated
screening to identify potential interactions involving drug pairs and triads that increase the risk of fall-related
injuries among NH residents with ADRD; Aim 2 (Testing), After prioritizing interaction screening results with the
guidance of a multidisciplinary expert stakeholder panel, perform a series of hypothesis-driven studies to quantify
the effects of drug interactions on fall-related injuries, including dose, duration, and NH resident subgroup effects;
and Aim 3 (Replication), Conduct a series of validation studies in independent data to determine whether the
drug interactions identified during screening and testing are consistently associated with fall-related injuries
among NH residents with ADRD. To accomplish the three proposed aims, a large novel database of NH
electronic health record information be leveraged along with national MDS 3.0 clinical assessment records linked
to Medicare health insurance and prescription drug claims. The proposed research is highly significant because
it will provide clinically actionable empirical evidence to help guide the prescribing, deprescribing, and
management of medications to minimize the risk of important drug interactions and fall-related injuries among
NH residents with ADRD. This proposal is directly responsive to PAR-19-070 and advances the National Institute
on Aging's Strategic Goal C to improve the safe use of medications.
项目摘要
多药治疗在疗养院(NH)居民中很常见,在患有以下疾病的居民中最普遍:
阿尔茨海默病和相关痴呆症(ADRD)由于其多种慢性疾病的高负担,
使他们倾向于使用药物。多重用药对患有ADRD的NH居民来说是危险的,因为它
大大增加了药物相互作用的风险。与跌倒有关的伤害,包括骨折,关节脱位,
药物相互作用的最常见和最具影响力的不良后果之一,
发病率残疾和死亡率药物之间的许多理论相互作用已被确定,
医疗保健提供者认为,药物相互作用在老年NH居民中是常见和有害的,
ADRD,但关于哪些相互作用最具临床意义的数据有限。鉴于药物相互作用
由多种药物引起的高血压可能是老年NH患者跌倒相关损伤的主要但可改变的原因
对于患有ADRD的居民,识别药物相互作用及其影响对于避免跌倒相关伤害至关重要。
因此,本提案的总体目标是识别、测试和验证具有临床意义的药物相互作用
通过一系列严格的流行病学研究,
交互筛选和因果推理方法。中心假设是多个临床显著
药物相互作用将增加跌倒相关损伤的风险,并且这种风险在个体中最大
最严重的认知障碍和更高的药物剂量。这一假设将得到检验
通过三个具体目标:目标1(筛选),进行无假设的高通量半自动化
筛选,以确定涉及药物对和三联体的潜在相互作用,这些药物对和三联体会增加跌倒相关的风险。
伤害NH居民与ADRD;目的2(测试),优先互动筛选结果后,
在多学科专家利益相关者小组的指导下,进行一系列假设驱动的研究,
药物相互作用对跌倒相关损伤的影响,包括剂量、持续时间和NH居民亚组影响;
和目标3(复制),在独立数据中进行一系列验证研究,以确定
在筛选和测试过程中发现的药物相互作用与跌倒相关损伤一致相关
在患有ADRD的NH居民中。为了实现这三个目标,一个大型的新的NH数据库
电子健康记录信息应与国家MDS 3.0临床评估记录一起沿着使用
医疗保险和处方药索赔。这项研究非常重要,因为
它将提供临床可操作的经验证据,以帮助指导处方,取消处方,
药物管理,以尽量减少重要药物相互作用和跌倒相关损伤的风险,
有ADRD的居民。该提案直接响应PAR-19-070,并推动国家研究所
关于老龄化的战略目标C,以提高药物的安全使用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Reis Zullo其他文献
Andrew Reis Zullo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Reis Zullo', 18)}}的其他基金
Clinically Significant Drug Interactions among Nursing Home Residents with ADRD
患有 ADRD 的疗养院居民中具有临床意义的药物相互作用
- 批准号:
10448110 - 财政年份:2022
- 资助金额:
$ 70.74万 - 项目类别:
Medications and the Risk of Motor Vehicle Crashes in Older Adults
老年人的药物和车祸风险
- 批准号:
10260401 - 财政年份:2020
- 资助金额:
$ 70.74万 - 项目类别:
Medications and the Risk of Motor Vehicle Crashes in Older Adults
老年人的药物和车祸风险
- 批准号:
10633192 - 财政年份:2020
- 资助金额:
$ 70.74万 - 项目类别:
Medications and the Risk of Motor Vehicle Crashes in Older Adults
老年人的药物和车祸风险
- 批准号:
10624520 - 财政年份:2020
- 资助金额:
$ 70.74万 - 项目类别:
Medications and the Risk of Motor Vehicle Crashes in Older Adults
老年人的药物和车祸风险
- 批准号:
10425421 - 财政年份:2020
- 资助金额:
$ 70.74万 - 项目类别:
相似海外基金
Artificial intelligence-based health IT tools to optimize critical care pharmacist resources through adverse drug event prediction
基于人工智能的健康 IT 工具,通过药物不良事件预测来优化重症监护药剂师资源
- 批准号:
10503268 - 财政年份:2022
- 资助金额:
$ 70.74万 - 项目类别:
Comparison of Hemorrhagic Risk between Prasugrel and Clopidogrel: a Retrospective Study using Adverse Drug Event Reporting Databases
普拉格雷和氯吡格雷出血风险的比较:使用药物不良事件报告数据库的回顾性研究
- 批准号:
18K14954 - 财政年份:2018
- 资助金额:
$ 70.74万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Adverse Reactions to Potent Opioids: An analysis using the largescale Japanese Adverse Drug Event Report database
对强效阿片类药物的不良反应:使用大型日本药物不良事件报告数据库进行的分析
- 批准号:
15K08111 - 财政年份:2015
- 资助金额:
$ 70.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Implementation and Evaluation of an Enhanced PharmaNet-Based Adverse Drug Event Reporting Platform to Improve Patient Safety and Meet Adverse Drug Reaction Reporting Requirements
基于 PharmaNet 的增强型药品不良事件报告平台的实施和评估,以提高患者安全并满足药品不良反应报告要求
- 批准号:
334597 - 财政年份:2015
- 资助金额:
$ 70.74万 - 项目类别:
Operating Grants
EMR Adverse Drug Event Detection for Pharmacovigilance
用于药物警戒的 EMR 药物不良事件检测
- 批准号:
9123554 - 财政年份:2014
- 资助金额:
$ 70.74万 - 项目类别:
EMR Adverse Drug Event Detection for Pharmacovigilance
用于药物警戒的 EMR 药物不良事件检测
- 批准号:
8772667 - 财政年份:2014
- 资助金额:
$ 70.74万 - 项目类别:
Integration of spatial epidemiology and pharmacoepidemiology for the practical use of the adverse drug event report database with related applications
空间流行病学和药物流行病学的整合,用于药物不良事件报告数据库的实际使用及相关应用
- 批准号:
26540012 - 财政年份:2014
- 资助金额:
$ 70.74万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Epidemiology of Adverse Drug Event in intensive care unit (ICU) and neonatal ICU (NICU)
重症监护病房(ICU)和新生儿重症监护病房(NICU)药品不良事件流行病学
- 批准号:
25860484 - 财政年份:2013
- 资助金额:
$ 70.74万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Optimizing Adverse Drug Event Reporting within a Provincial Medication Information System to Improve Pharmacovigilence and Inform Pharmaceutical Policy
优化省级药品信息系统内的药品不良事件报告,以提高药物警戒并为药品政策提供信息
- 批准号:
284162 - 财政年份:2013
- 资助金额:
$ 70.74万 - 项目类别:
Fellowship Programs
Adverse Drug Event Reporting in PharmaNet to Improve Patient Safety and Inform Policy
PharmaNet 中的药物不良事件报告可提高患者安全并为政策提供信息
- 批准号:
273419 - 财政年份:2012
- 资助金额:
$ 70.74万 - 项目类别:
Operating Grants